DK0792643T3 - Anvendelse af en aldosereduktaseinhibitor til at reducere skade på ikke-cardialt væv - Google Patents

Anvendelse af en aldosereduktaseinhibitor til at reducere skade på ikke-cardialt væv

Info

Publication number
DK0792643T3
DK0792643T3 DK97301172T DK97301172T DK0792643T3 DK 0792643 T3 DK0792643 T3 DK 0792643T3 DK 97301172 T DK97301172 T DK 97301172T DK 97301172 T DK97301172 T DK 97301172T DK 0792643 T3 DK0792643 T3 DK 0792643T3
Authority
DK
Denmark
Prior art keywords
tissue damage
reductase inhibitor
cardiac tissue
aldose reductase
reduce non
Prior art date
Application number
DK97301172T
Other languages
English (en)
Inventor
Eric R Pettipher
Delvin R Knight Jr
Banavara L Mylari
Peter J Oates
Wayne R Tracey
Thomas A Beyer
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0792643T3 publication Critical patent/DK0792643T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01021—Aldehyde reductase (1.1.1.21), i.e. aldose-reductase

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DK97301172T 1996-02-29 1997-02-21 Anvendelse af en aldosereduktaseinhibitor til at reducere skade på ikke-cardialt væv DK0792643T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1270796P 1996-02-29 1996-02-29

Publications (1)

Publication Number Publication Date
DK0792643T3 true DK0792643T3 (da) 2002-07-22

Family

ID=21756300

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97301172T DK0792643T3 (da) 1996-02-29 1997-02-21 Anvendelse af en aldosereduktaseinhibitor til at reducere skade på ikke-cardialt væv

Country Status (14)

Country Link
US (1) US6127367A (da)
EP (1) EP0792643B1 (da)
JP (1) JPH09316003A (da)
KR (1) KR970061252A (da)
CN (1) CN1081460C (da)
AT (1) ATE216239T1 (da)
AU (1) AU724327B2 (da)
CA (1) CA2198564C (da)
DE (1) DE69711972T2 (da)
DK (1) DK0792643T3 (da)
ES (1) ES2172748T3 (da)
IL (1) IL120264A0 (da)
PT (1) PT792643E (da)
ZA (1) ZA971717B (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0982306A3 (en) * 1998-08-21 2000-07-05 Pfizer Products Inc. Polymorph of zopolrestat monohydrate
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2002098421A1 (en) * 2001-06-05 2002-12-12 University Of Maryland, Baltimore Novel treatment for neurological and psychiatric disorders
EP1501822B1 (en) 2002-04-30 2010-12-15 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
ES2393271T3 (es) * 2005-12-16 2012-12-19 Sanwa Kagaku Kenkyusho Co., Ltd Agente para la prevención y tratamiento de la insuficiencia renal aguda
KR20080108465A (ko) * 2006-02-20 2008-12-15 가부시키가이샤산와카가쿠켄큐쇼 뇌졸중에 있어서의 뇌허혈 또는 뇌허혈 재관류 장해의 예방또는 치료제
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
AU2008210970B2 (en) * 2007-01-31 2012-11-29 Sanwa Kagaku Kenkyusho Co., Ltd. Protective agent for retinal nerve or optic nerve
EP2139330B1 (en) * 2007-03-23 2014-09-24 The Board of Regents of The University of Texas System Methods involving aldose reductase inhibitors
MX2010002749A (es) 2007-09-14 2010-06-25 Astrazeneca Ab Derivados de ftalazinona.
MX2010004028A (es) 2007-10-17 2010-04-30 Kudos Pharm Ltd 4-[3-(4-ciclopropancarbonil-piperacin-1-carbonil)-4-fluoro-bencil ]-2h-ftalacin-1-ona.
CA2705376A1 (en) * 2007-11-15 2009-05-22 Universite Laval Methods for the regulation of the prostaglandin f synthase (pgfs) activity of akr1b1 and uses thereof
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
UA106878C2 (uk) 2008-10-07 2014-10-27 Астразенека Юк Лімітед Фармацевтична композиція, що містить 4-[3-(4-циклопропанкарбонілпіперазин-1-карбоніл)-4-фторбензил]-2н-фталазин-1-он або його сіль, або сольват, у твердій дисперсії з матричним полімером коповідоном
EP2654749B1 (en) 2010-12-23 2017-05-10 The Board of Regents of The University of Texas System Methods for treating copd
EP3529410B1 (en) 2016-10-19 2022-04-20 Spectrum Brands, Inc. Portable steam generator base for iron
WO2022197487A1 (en) 2021-03-18 2022-09-22 Banavara MYLARI Combination of aldose reductase inhibitors and probenecid for the treatment of diabetic complications
WO2024053761A1 (ko) * 2022-09-07 2024-03-14 애니머스큐어 주식회사 알도오즈 환원효소 억제제를 포함하는 근원 세포 증식 및 분화 촉진용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4492706A (en) * 1983-08-01 1985-01-08 American Home Products Corporation Method of lowering lipid levels
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
EP0310931A3 (en) * 1987-10-08 1990-10-03 Ethyl Corporation Poultry feed
FR2665440B1 (fr) * 1990-07-31 1994-02-04 Lipha Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant.
US5064830A (en) * 1990-08-02 1991-11-12 Pfizer Inc. Lowering of blood uric acid levels
JP3049284B2 (ja) * 1990-11-07 2000-06-05 株式会社三和化学研究所 ヒダントイン誘導体並びにそれを有効成分とする糖尿病合併症及び循環器系疾患の予防及び治療剤
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
JP2002504884A (ja) * 1994-12-22 2002-02-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 虚血から心臓を保護する方法
US5834466A (en) * 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
CZ293016B6 (cs) * 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem

Also Published As

Publication number Publication date
IL120264A0 (en) 1997-06-10
CA2198564C (en) 2000-06-27
MX9701533A (es) 1998-06-30
CA2198564A1 (en) 1997-08-29
ATE216239T1 (de) 2002-05-15
KR970061252A (ko) 1997-09-12
JPH09316003A (ja) 1997-12-09
DE69711972T2 (de) 2002-08-29
CN1081460C (zh) 2002-03-27
ES2172748T3 (es) 2002-10-01
CN1168794A (zh) 1997-12-31
PT792643E (pt) 2002-08-30
EP0792643B1 (en) 2002-04-17
DE69711972D1 (de) 2002-05-23
AU724327B2 (en) 2000-09-14
US6127367A (en) 2000-10-03
AU1501097A (en) 1997-09-04
EP0792643A1 (en) 1997-09-03
ZA971717B (en) 1998-08-27

Similar Documents

Publication Publication Date Title
DK0792643T3 (da) Anvendelse af en aldosereduktaseinhibitor til at reducere skade på ikke-cardialt væv
TR200200129T2 (tr) Hepatit C inhibitörü tri-peptidler
AR015379A1 (es) Ascorbil-fosforil-colesterol
BR9707791A (pt) Corpo ótico
DE69902953D1 (de) Optischer Kopf
DE69503640D1 (de) Am kopf montierte anzeigeoptik
FI953592A (fi) 2-(2-amino-1,6-dihydro-6-oksopurin-9-yyli)metoksi-1,3-propaanidiolijohdannainen
DE59700907D1 (de) Monolithische laserdioden-modulator-kombination
FI930632A (fi) Kytkentä lähetinvahvistimen tehon säätämiseksi
NO20011966D0 (no) Serin-protease-inhibitor
DE69832431D1 (de) N-Weg-RF-Leistungsaddierer/-verteiler
NO985497D0 (no) Trykkf°lsomt br°nnverkt°y med en mellomtrinn-trykkstilling
ATE305881T1 (de) Strukturbauteil
DE69419550D1 (de) Optischer Kopf
DE60023852D1 (de) Objektivlinse
DE69932138D1 (de) Optischer Kopf
ITMI930499V0 (it) Sottopiede ad elevate prestazioni tecniche
DE69726053D1 (de) Optischer Kopf
DK0791355T3 (da) Fremgangsmåde til reduktion af vævsbeskadigelse forbundet med iskæmi
DE60100777D1 (de) Optischer Wellenlängenkonverter
DE69717571D1 (de) Optischer Kopf
DE69418528D1 (de) Optischer Kopf
FI982327A0 (fi) Sovitelma puhelimen handsfree-toiminnoksi
NO960333D0 (no) Tiazol-derivater som lipoksygenase-inhibitorer
KR930024341U (ko) 리미트 스위치의 파손 방지용 레버